PharmaBlock Sciences (Nanjing) , Inc.

PharmaBlock was officially operated in 2008 as a provider of drug-like small molecule building blocks and has since evolved into a fully integrated CRDMO partner following its IPO in 2017 (Stock Code: 300725.SZSE). Today, the company offers end-to-end solutions spanning from early-stage discovery to commercial manufacturing, with expanding capabilities in emerging modalities such as oligonucleotides, peptides, and complex conjugates. PharmaBlock’s strategy is anchored in advancing sustainability through innovation in green and intelligent chemistry to empower next-generation therapies. In discovery, the company has advanced its building blocks into “PharmaChips” for next generation therapies including novel and high-purity short peptides, amidites and conjugate linkers. Leveraging three distinctive libraries: a DNA-encoded library, a fragment library, and an ultra-large, synthetically accessible virtual library and AI technologies, it enables customers to accelerate hit discovery and lead optimization In development, drawing on extensive experience in the production of thousands of building blocks, PharmaBlock has built a strong green and intelligent technology platform for both development and manufacturing. This platform includes flow chemistry, process modeling, computational fluid dynamics (CFD), bio-/metal catalysis, high-throughput experimentation (HTE), process analytical technology (PAT), and digitalization, as well as advanced capabilities in Liquid Phase Peptide Synthesis (LPPS). These capabilities allow the company to address complex chemistry challenges, reduce development risks, and minimize environmental impact. Committed to green and intelligent chemistry, PharmaBlock combines speed with sustainability. Its global “region-for-region” model ensures fast turnaround, reliable supply, and consistent quality for partners worldwide.